Achilles Therapeutics PLC ADR (ACHL)

Name: Achilles Therapeutics PLC ADR (ACHL) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Achilles Therapeutics PLC ADR (ACHL)

Stock Card

$1.48

$0.00 (0.00%)

As on 26-Mar-2025 09:30EDT

Market cap

$63 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.6

Div. Yield

0 %

Achilles Therapeutics PLC ADR (ACHL) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.48 High: 1.48

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.7
Debt to Equity

0
Book Value

$--
EPS

$-1.7
Face value

--
Shares outstanding

41,100,000

6 Years Aggregate

CFO

$-214.45 Mln

EBITDA

$-262.28 Mln

Net Profit

$-249.40 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Achilles Therapeutics PLC ADR (ACHL)	29.8	8.0	29.8	20.3	-22.3	--	--
BSE Sensex^*	-9.5	-2.5	3.1	-4.9	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 26-Mar-2025 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022
Achilles Therapeutics PLC ADR (ACHL)	28.0	-1.2	-82.0
S&P Small-Cap 600	7.0	13.9	-17.4
BSE Sensex	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Achilles Therapeutics PLC ADR (ACHL)

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered... bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. Read more

CEO & Director

Dr. Iraj Ali Ph.D.
CEO & Director

Dr. Iraj Ali Ph.D.
Headquarters

London
Website

https://www.achillestx.com

FAQs for Achilles Therapeutics PLC ADR (ACHL)

What is the current share price of Achilles Therapeutics PLC ADR (ACHL) Today?

The share price of Achilles Therapeutics PLC ADR (ACHL) is $1.48 (NASDAQ) as of 26-Mar-2025 09:30 EDT. Achilles Therapeutics PLC ADR (ACHL) has given a return of -22.26% in the last 3 years.

What is the current PB & PE ratio of Achilles Therapeutics PLC ADR (ACHL)?

Since, TTM earnings of Achilles Therapeutics PLC ADR (ACHL) is negative, P/E ratio is not available.
The P/B ratio of Achilles Therapeutics PLC ADR (ACHL) is 0.61 times as on 26-Mar-2025, a 88 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-0.51	0.25
2022	-0.49	0.18
2021	-2.38	0.50
2020	--	--
2019	--	--

What is the 52 Week High and Low of Achilles Therapeutics PLC ADR (ACHL)?

The 52-week high and low of Achilles Therapeutics PLC ADR (ACHL) are Rs -- and Rs -- as of 04-Sep-2026.

What is the market cap of Achilles Therapeutics PLC ADR (ACHL)?

Achilles Therapeutics PLC ADR (ACHL) has a market capitalisation of $ 63 Mln as on 26-Mar-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Achilles Therapeutics PLC ADR (ACHL)?

Before investing in Achilles Therapeutics PLC ADR (ACHL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.